Beschreibung
Carbamazepine dramatically reduces aripiprazole plasma levels through potent CYP3A4 induction, potentially rendering antipsychotic treatment ineffective.
Mechanismus
Carbamazepine induces CYP3A4, the primary enzyme metabolizing aripiprazole, reducing aripiprazole AUC by approximately 70%.
Klinische Bedeutung
Psychiatric relapse due to sub-therapeutic aripiprazole levels is a major risk; FDA labeling explicitly requires a dose doubling.
Maßnahmen
Double aripiprazole dose when co-prescribed with carbamazepine per FDA label; monitor clinical response and reduce dose if carbamazepine is discontinued.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.